Sign In
Last checked at 
3 Jun 2014 12:34
Oxford BioMedica plc Annual General Meeting
Oxford, UK - 03 June 2014: Oxford BioMedica ("the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, announced today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.
In accordance with Listing Rule 9.6.18 the following resolutions are those which were passed at the meeting concerning special business:
· Resolution 8: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares; and
· Resolution 9: to permit the Company to convene general meetings (other than annual general meetings) on not less than 14 days' notice.
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxfordbiomedica.co.uk.
Certified copies of the document setting out the above resolutions passed at the 2014 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/NSM.
The results of the proxy voting in advance of the meeting are shown below. On the Record Date (1 June 2014) there were 1,416,149,005 1p ordinary shares in issue, each carrying one vote per share.
Resolution |
Votes For | Votes at Chairman's Discretion | Votes at other proxy Discretion |
Votes Against |
Votes Withheld |
Total votes cast | Result |
Ordinary resolutions | |||||||
1 | 666,687,905 | 923,289 | 8,075,255 | 38,902 | 42,532 | 675,767,883 | Passed |
2 | 271,899,678 | 855,355 | 8,075,255 | 30,865,202 | 364,072,393 | 675,767,883 | Passed |
3 | 302,233,865 | 862,795 | 8,075,255 | 457,303 | 364,138,665 | 675,767,883 | Passed |
4 | 666,042,751 | 835,902 | 8,075,255 | 717,073 | 96,902 | 675,767,883 | Passed |
5 | 666,025,533 | 849,296 | 8,075,255 | 691,964 | 125,835 | 675,767,883 | Passed |
6 | 665,987,201 | 1,012,357 | 8,075,255 | 634,469 | 58,601 | 675,767,883 | Passed |
7 | 666,254,034 | 1,040,107 | 8,075,255 | 266,422 | 132,065 | 675,767,883 | Passed |
Special resolutions | |||||||
8 | 665,722,262 | 1,021,371 | 8,075,255 | 789,363 | 159,632 | 675,767,883 | Passed |
9 | 661,187,722 | 1,021,229 | 8,075,255 | 612,921 | 4,870,756 | 675,767,883 | Passed |
-Ends-
For further information, please contact: |
|
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer |
Tel: +44 (0)1865 783 000 |
|
|
Media Enquiries: Mary-Jane Elliott/Emma Thompson/Matthew Neal Consilium Strategic Communications | Tel: +44 (0)20 3709 5700 |
Notes to editors
Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.
Follow the stocks
